story of the week
Adjuvant Atezolizumab vs Observation in Muscle-Invasive Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant Atezolizumab Versus Observation in Muscle-Invasive Urothelial Carcinoma (IMvigor010): A Multicentre, Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2021 Mar 12;[EPub Ahead of Print], J Bellmunt, M Hussain, JE Gschwend, P Albers, S Oudard, D Castellano, S Daneshmand, H Nishiyama, M Majchrowicz, V Degaonkar, Y Shi, S Mariathasan, P Grivas, A Drakaki, PH O'Donnell, JE Rosenberg, DM Geynisman, DP Petrylak, J Hoffman-Censits, J Bedke, AR Kalebasty, Y Zakharia, MS van der Heijden, CN Sternberg, NN Davarpanah, T Powles, IMvigor010 Study GroupFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.